Hospital

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.

Investigators found that younger age groups had significantly longer lengths of stay compared to those older than 75 years.

Investigators found that 89% of individuals with cardiovascular disease consumed more than 1500 mg of sodium daily.

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

The primary endpoint of the study was clinical remission at week 52 with vedolizumab

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

Regardless of how this fits into workflow, pharmacists can play a significant role in counseling patients on nutrition and holistic health.

The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.

The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.

IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.

AI offers many benefits in health professions by efficiently handling time-consuming tasks crucial for patient care.

The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.

The 5-in-1 meningococcal ABCWY vaccine candidate has an assigned Prescription Drug User Fee Act action date of February 14, 2025.

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some common challenges pharmacists may be facing when looking to operationalize bispecifics at their facilities.

Investigators also found that the pneumococcal conjugate vaccine 13 protected against nasopharyngeal carriage in children and provided some indirect protection for adults.

Although the vaccine has not yet been tested in humans, it demonstrated 100% efficacy in protecting primates who were injected with human Marburg virus disease.

SGLT-2 inhibitors reduce cardiovascular deaths, heart failure hospitalizations, hyperkalemia, and decline of renal function in patients with HFrEF.

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.

The designation was granted based on overall survival data from an ongoing randomized phase 2 clinical trial.

Both dual primary endpoints—progression-free survival and overall survival—were met with durvalumab.